Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Mesoblast Limited — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.3 (market cap $510.01M), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 3.4× GraniteShares 2x Long COIN Daily ETF's market cap, and Mesoblast Limited is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Mesoblast Limited for 15 Days on average.
| CONL | MESO | |
|---|---|---|
Market Cap | $510.01M | $1.75B |
Volume | 21,041,836 | 239,027 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $20.96 |
52-Week Low | $3.93 | $13.19 |
Typical Hold Time | 15 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $5.41, up 3.44% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF, which provides 2x daily leveraged exposure to Coinbase Global stock, faces volatility from its underlying asset's performance. Recent news highlights significant price gaps and volume spikes, with the stock previously gapping up to $6.44 on October 1, 2026.
The outlook remains high-risk due to leveraged structure amplifying Coinbase's volatility. Investment opportunity exists for short-term traders betting on Coinbase rebounds, but risks include rapid decay from daily rebalancing and crypto market downturns. Long-term holders face erosion from volatility drag, requiring careful risk management.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
